01922nas a2200277   4500000000100000000000100001008004100002260001500043653001800058653001800076100002100094700001700115700001900132700002200151700001800173700002700191700001700218700001700235700001500252245014200267856005500409300000900464490000600473520115100479022001401630       2023                            d  c2023-11-1310aCancer models10aLab-on-a-chip1 aEliana Steinberg1 aRoy Friedman1 aYoel Goldstein1 aNethanel Friedman1 aOfer Beharier1 aJonathan Abraham Demma1 aGideon Zamir1 aAyala Hubert1 aOfra Benny00aA fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine  uhttps://www.nature.com/articles/s42003-023-05531-5  a1-140 v63 aOptimal clinical outcomes in cancer treatments could be achieved through the development of reliable, precise ex vivo tumor models that function as drug screening platforms for patient-targeted therapies. Microfluidic tumor-on-chip technology is emerging as a preferred tool since it enables the complex set-ups and recapitulation of the physiologically relevant physical microenvironment of tumors. In order to overcome the common hindrances encountered while using this technology, a fully 3D-printed device was developed that sustains patient-derived multicellular spheroids long enough to conduct multiple drug screening tests. This tool is both cost effective and possesses four necessary characteristics of effective microfluidic devices: transparency, biocompatibility, versatility, and sample accessibility. Compelling correlations which demonstrate a clinical proof of concept were found after testing and comparing different chemotherapies on tumor spheroids, derived from ten patients, to their clinical outcomes. This platform offers a potential solution for personalized medicine by functioning as a predictive drug-performance tool.  a2399-3642